272 related articles for article (PubMed ID: 7535147)
1. The clinical utility of granulocyte colony-stimulating factor: early achievements and future promise.
Morstyn G; Foote M; Perkins D; Vincent M
Stem Cells; 1994; 12 Suppl 1():213-27; discussion 227-8. PubMed ID: 7535147
[TBL] [Abstract][Full Text] [Related]
2. Granulocytic growth factors and cancer-related neutropenia: limited effects.
Prescrire Int; 2006 Oct; 15(85):189-91. PubMed ID: 17128529
[TBL] [Abstract][Full Text] [Related]
3. Contribution of glycosylated recombinant human granulocyte colony-stimulating factor (lenograstim) use in current cancer treatment: review of clinical data.
Gunzer K; Clarisse B; Lheureux S; Delcambre C; Joly F
Expert Opin Biol Ther; 2010 Apr; 10(4):615-30. PubMed ID: 20218922
[TBL] [Abstract][Full Text] [Related]
4. Granulocyte colony-stimulating factor treatment for cyclophosphamide-induced severe neutropenia in Wegener's granulomatosis.
Hellmich B; Schnabel A; Gross WL
Arthritis Rheum; 1999 Aug; 42(8):1752-6. PubMed ID: 10446877
[TBL] [Abstract][Full Text] [Related]
5. Human granulocyte colony-stimulating factor (rHuG-CSF) for treatment of neutropenia in Shwachman syndrome.
Ventura A; Dragovich D; Luxardo P; Zanazzo G
Haematologica; 1995; 80(3):227-9. PubMed ID: 7545636
[TBL] [Abstract][Full Text] [Related]
6. Future strategy for cancer treatment using recombinant human granulocyte colony stimulating factor.
Diehl V
Eur J Cancer; 1994; 30A Suppl 3():S44-7. PubMed ID: 7535072
[TBL] [Abstract][Full Text] [Related]
7. Efficacy and safety of two different rG-CSF preparations in the treatment of patients with severe congenital neutropenia.
Carlsson G; Ahlin A; Dahllöf G; Elinder G; Henter JI; Palmblad J
Br J Haematol; 2004 Jul; 126(1):127-32. PubMed ID: 15198743
[TBL] [Abstract][Full Text] [Related]
8. Use of recombinant human granulocyte colony-stimulating factor in children given allogeneic bone marrow transplantation for acute or chronic leukemia.
Locatelli F; Pession A; Zecca M; Bonetti F; Prete L; Carrà AM; Prete A; Montagna D; Comoli P; Taibi RM; Paolucci G
Bone Marrow Transplant; 1996 Jan; 17(1):31-7. PubMed ID: 8673051
[TBL] [Abstract][Full Text] [Related]
9. Prophylactic granulocyte colony-stimulating factor and granulocyte-macrophage colony-stimulating factor decrease febrile neutropenia after chemotherapy in children with cancer: a meta-analysis of randomized controlled trials.
Sung L; Nathan PC; Lange B; Beyene J; Buchanan GR
J Clin Oncol; 2004 Aug; 22(16):3350-6. PubMed ID: 15310780
[TBL] [Abstract][Full Text] [Related]
10. Prophylactic administration of granulocyte colony-stimulating factor (filgrastim) after conventional chemotherapy in children with cancer.
Riikonen P; Rahiala J; Salonvaara M; Perkkiö M
Stem Cells; 1995 May; 13(3):289-94. PubMed ID: 7542114
[TBL] [Abstract][Full Text] [Related]
11. Granulocyte colony-stimulating factors in the management of chemotherapy-induced neutropenia: evidence based review.
Bhana N
Curr Opin Oncol; 2007 Jul; 19(4):328-35. PubMed ID: 17545795
[TBL] [Abstract][Full Text] [Related]
12. Effects of a formulary change from granulocyte colony-stimulating factor to granulocyte-macrophage colony-stimulating factor on outcomes in patients treated with myelosuppressive chemotherapy.
Wong SF; Chan HO
Pharmacotherapy; 2005 Mar; 25(3):372-8. PubMed ID: 15843284
[TBL] [Abstract][Full Text] [Related]
13. Randomized comparison of antibiotics with and without granulocyte colony-stimulating factor in children with chemotherapy-induced febrile neutropenia: a report from the Children's Oncology Group.
Ozkaynak MF; Krailo M; Chen Z; Feusner J
Pediatr Blood Cancer; 2005 Sep; 45(3):274-80. PubMed ID: 15806544
[TBL] [Abstract][Full Text] [Related]
14. The clinical benefits of recombinant human granulocyte colony stimulating factor in the treatment of cancer patients.
Bacigalupo A
Eur J Cancer; 1994; 30A Suppl 3():S26-9. PubMed ID: 7535069
[TBL] [Abstract][Full Text] [Related]
15. Role of granulocyte colony stimulating factor (G-CSF) in chemotherapy induced neutropenia.
Ghalaut PS; Sen R; Dixit G
J Assoc Physicians India; 2008 Dec; 56():942-4. PubMed ID: 19322972
[TBL] [Abstract][Full Text] [Related]
16. Glycosylation of recombinant human granulocyte colony stimulating factor: implications for stability and potency.
Nissen C
Eur J Cancer; 1994; 30A Suppl 3():S12-4. PubMed ID: 7535065
[TBL] [Abstract][Full Text] [Related]
17. Lenograstim. A review of its pharmacological properties and therapeutic efficacy in neutropenia and related clinical settings.
Frampton JE; Yarker YE; Goa KL
Drugs; 1995 May; 49(5):767-93. PubMed ID: 7541335
[TBL] [Abstract][Full Text] [Related]
18. Correction of neutropenia with rHuG-CSF after loss of response to rHuGM-CSF following autologous bone marrow transplant.
Boulad F; Gillio A; Small TN; Bonilla MA; Philips P; Ruggiero M; Emanuel D; Ghavimi F; Kernan NA
Bone Marrow Transplant; 1994 May; 13(5):661-3. PubMed ID: 7519939
[TBL] [Abstract][Full Text] [Related]
19. Recombinant human granulocyte-macrophage colony-stimulating factor in combination with antibiotics in the treatment of febrile neutropenia in children.
Riikonen P
Stem Cells; 1995 May; 13(3):201-5. PubMed ID: 7613488
[TBL] [Abstract][Full Text] [Related]
20. Effect of granulocyte-colony stimulating factor on empiric therapy with flomoxef sodium and tobramycin in febrile neutropenic patients with hematological malignancies. Kan-etsu Hematological Disease and Infection Study Group.
Yoshida M; Karasawa M; Naruse T; Fukuda M; Hirashima K; Oh H; Ninomiya H; Abe T; Saito K; Shishido H; Moriyama Y; Shibata A; Motoyoshi K; Nagata N; Miura Y
Int J Hematol; 1999 Feb; 69(2):81-8. PubMed ID: 10071455
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
